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Abstract
CYP2C19 genotype-guided antiplatelet therapy following percutaneous coronary intervention is 
increasingly implemented in clinical practice. However, challenges such as selecting a testing 
platform, communicating test results, building clinical decision support processes, providing 
patient and provider education, and integrating methods to support the translation of emerging 
evidence to clinical practice are barriers to broad adoption. In this report, we compare and contrast 
implementation strategies of 12 early adopters, describing solutions to common problems and 
initial performance metrics for each program. Key differences between programs included the test 
result turnaround time and timing of therapy changes which are both related to CYP2C19 testing 
model and platform used. Sites reported the need for new informatics infrastructure, expert 
clinicians such as pharmacists to interpret results, physician champions, and ongoing education. 
Consensus lessons learned are presented to provide a path forward for those seeking to implement 
similar clinical pharmacogenomics programs within their institutions.
Keywords
pharmacogenomics; implementation; CYP2C19; percutaneous coronary intervention
Introduction
Cytochrome p450 2C19 (CYP2C19) genotyping for antiplatelet therapy selection after 
percutaneous coronary intervention (PCI) is one of the leading clinical pharmacogenomics 
implementation scenarios in the United States.1 Consensus standard-of-care 
pharmacotherapy post-PCI consists of dual antiplatelet therapy with aspirin and a P2Y12 
receptor inhibitor, namely clopidogrel, prasugrel, or ticagrelor.2 Clopidogrel still remains the 
Empey et al. Page 2
Clin Pharmacol Ther. Author manuscript; available in PMC 2019 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
most commonly prescribed due to lower cost, better accessibility, and lower risk of non-
coronary artery bypass graft major bleeding compared to newer agents.3–5
Clopidogrel is a prodrug that requires bioactivation to an active metabolite for therapeutic 
effect. Although multiple enzymes are involved in clopidogrel metabolism, only genetic 
variation in CYP2C19 has been consistently associated with alterations in clopidogrel 
pharmacokinetics and pharmacodynamic responses.6–8CYP2C19 loss-of-function alleles 
that produce a nonfunctional enzyme, now described as nonfunctional alleles by the Clinical 
Pharmacogenetics Implementation Consortium (CPIC),9 are common occurring in 
approximately 30% of Europeans, 30% of Africans, and 60% of Asians.10 Retrospective 
analyses of clinical trial and patient registry data have shown that compared with 
clopidogrel-treated individuals with two functional alleles of CYP2C19, similarly-treated 
patients carrying at least one nonfunctional allele have an increased risk of cardiovascular 
events after PCI.11,12 Clinical outcomes during treatment with the third generation P2Y12 
inhibitors prasugrel and ticagrelor are unaffected by CYP2C19 genotype.13,14
The Food and Drug Administration added a boxed warning to the clopidogrel labeling in 
2010 stating that clopidogrel effectiveness is reduced in CYP2C19 poor metabolizers (PMs), 
who have two no-function variant alleles, and alternative treatments should be considered in 
these patients.15 CPIC guidelines recommend alternative therapy in PMs as well as 
intermediate metabolizers (IMs), who have a single nonfunctional allele; however, they do 
not address whether the test should be routinely performed.10 Joint guidelines for PCI by the 
American Heart Association (AHA) and American College of Cardiology (ACC) state that 
CYP2C19 genetic testing, and tailoring antiplatelet therapy based on the result might be 
considered in high-risk patients; however, these guidelines recommend against the routine 
clinical use of genetic testing for PCI patients, based on the absence of data from large 
randomized controlled trials.2 Since the publication of these guidelines, recent data from the 
IGNITE (Implementing GeNomics in PracTice) Network (www.ignite-genomics.org) 
demonstrate that among patients genotyped at the time of PCI, there is a lower risk of major 
adverse cardiovascular events in patients with a CYP2C19 nonfunctional allele treated with 
prasugrel or ticagrelor compared with nonfunctional allele carriers treated with clopidogrel.
16
A number of institutions now clinically test for CYP2C19 genotype in patients undergoing 
PCI, with more institutions likely to follow. Challenges that arise when offering a 
pharmacogenomic test include the selection of a testing platform, communication of test 
results, developing clinical decision support (CDS), patient education, and methods to 
support the translation of emerging evidence to clinical practice. We have gathered strategies 
to address these challenges from early adopters of genotype-guided antiplatelet therapy. The 
purpose of this paper is to summarize pathways to operationalizing CYP2C19 genotype-
guided antiplatelet therapy and approaches to overcome key obstacles likely to arise during 
this implementation.
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Results
Baseline institutional landscape and CYP2C19 implementation planning
Twelve large academic institutions in the IGNITE Network Pharmacogenetics Working 
Group that had implemented CYP2C19 genotype-guided antiplatelet therapy after PCI are 
included in this analysis (Table 1).1CYP2C19–clopidogrel was the first clinical 
pharmacogenomic implementation launched at 9 of the 12 institutions. The University of 
Illinois at Chicago had previously implemented CYP2C9/VKORC1–warfarin 
pharmacogenomic testing17, Vanderbilt University had launched the PREDICT program that 
focused on six gene–drug pairs, including CYP2C19–clopidogrel18, and Sanford Health had 
launched the Imagenetics program that tested eight pharmacogenes, including CYP2C19.19
The majority of programs were designed primarily as clinical versus research 
implementations (7 of 12 programs) with all but one of these submitting bills to third-party 
payers or patients for test reimbursement. Program oversight involved multiple collaborating 
stakeholders led by a formal precision medicine group at 9 of 12 institutions. Individual 
champions, including pharmacists, the cardiac catheterization laboratory director, and 
cardiology or primary care providers, led initiatives at the University of Illinois at Chicago, 
University of North Carolina at Chapel Hill, and Sanford Health, respectively. Program 
development time varied considerably across institutions and ranged from 6 to 24 months.
CYP2C19 targeted populations, ordering procedures, and testing
Eight of 12 institutions employed a reactive genotype testing model, in which the test was 
ordered in response to a PCI procedure with test results available soon after to guide 
antiplatelet medication therapy. In these instances, the indication for CYP2C19 testing 
generally included all patients undergoing PCI, with some sites further focusing on higher-
risk populations (i.e., presence of acute coronary syndrome (ACS) or high-risk anatomical 
features). Four institutions implemented a preemptive model with CYP2C19 testing 
performed in advance of any immediate need for test results. These programs used a 
predictive model to identify targeted populations with high probability of future PCI or 
clopidogrel use. Regardless of the testing model, all institutions included inpatients and 
outpatients [patients undergoing elective procedures with short (<24 hour) hospitalization 
stays] in their study populations.
The size of the target patient population varied considerably among sites based on cardiac 
catheterization laboratory PCI volume. Some research-based programs focused on narrow 
populations, with exclusion criteria applied based on research aims. CYP2C19 test ordering 
processes for sites with clinical implementation programs varied. The majority of programs 
(5 of 7 sites) depended on a prescriber to select CYP2C19 test on the post-PCI order set 
(opt-in), with the remainder incorporating a pre-selected test order on the post-PCI order set 
so that all patients undergoing PCI were genotyped unless the test was deselected (opt-out).
CYP2C19 assay and reporting methodologies are shown in Table 2. All tests were 
performed using validated laboratory developed tests in College of American Pathologists/
Clinical Laboratory Improvement Amendment (CAP/CLIA)-certified laboratories as 
necessary for performing testing within clinical care. Genotyping was performed using a 
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variety of platforms, with all institutions testing and reporting allele-defining variants for *2, 
*3, and *17 at minimum. All but three institutions had protocols to allow for biobanking of 
genetic samples as part of the implementation program (either to an institutional biobank or 
as part of a research-based implementation).
Communication of results, approach to therapy modification, and education strategies
All institutions reported CYP2C19 test results in the electronic health record (EHR). Results 
were documented in the “laboratory results” section of the EHR, often as discrete genotype 
and phenotype results (e. g. CYP2C19 *1/*2 and CYP2C19 Intermediate Metabolizer, 
respectively) with a linked text-based full report (9 of 12 sites). At three institutions, the 
patient genotype or phenotype was also recorded on the perpetual patient “problem list” 
(Table 3). The laboratory report included CYP2C19 genotype and predicted phenotype 
(metabolizer status) without patient-specific genotype-guided drug recommendations at 11 
of 12 institutions (Indiana University provided a drug therapy recommendation on the 
laboratory report).
A variety of different methods were used to communicate test results to providers and 
patients (Figure 1). Institutions with clinical implementation models generally relied on 
pharmacists or dedicated teams/services to provide genotype-informed drug therapy 
recommendations. Institutions with primarily research testing models also included study 
staff in this process. Four institutions relied solely on CDS or messaging for therapeutic 
recommendations and only Vanderbilt University used interruptive CDS delivered 
immediately after the test result. Eight of 12 sites provided downstream alerting or CDS 
triggered with future clopidogrel orders within the EHR. Three programs actively reported 
test results to downstream providers outside of their institution (e.g., a letter with the test 
result was sent to the primary care practitioner or cardiologist). Three programs routinely 
provided patients with their test results via a letter/report, patient web portal, an “ID” card 
with genotype results, and/or personal communication. Nine programs (including one of the 
above that also provided patients with their test results) introduced patients to CYP2C19 
testing through in-person education and/or disseminated brochures, pamphlets, or flyers. 
Although a number of provider education strategies were used, focused discussions with 
providers or in-services were perceived by most sites as being the most effective strategies.
Performance metrics
Median length of hospital stay for genotyped patients was one day (range 1-3 days) across 
all institutions. Testing process metrics and phenotype frequencies are provided in Table S1. 
Median genotype turnaround time (TAT), defined as each institution’s median time from 
genotype order to result appearing in the EHR, varied widely among institutions, from very 
short (1 to 5 hours with rapid testing platforms such as Spartan RX), to 1-3 days with 
standard single-gene test platforms in reactive models (GenMark eSensor XT-8 or custom 
Taqman® assays), to longer (6 to 8 days) for those institutions who used preemptive panel-
based or send-out testing strategies. Real-world CYP2C19 phenotype frequencies were 
similar across all sites, and consistent with those reported in clinical studies and established 
guidelines.16 All institutions followed CPIC guidelines that recommend alternative therapy 
(prasugrel or ticagrelor) for CYP2C19 IMs or PMs, and clopidogrel for CYP2C19 normal, 
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rapid, and ultrarapid metabolizers (*1/*1, *1/*17, and *17/*17 genotypes, respectively).10 
Triple dose clopidogrel (225 mg/day) was rarely used.16
Eight of 12 institutions provided data on downstream medication use for 1858 total patients 
who underwent genetic testing. Figure 2 depicts the proportions of patients with and without 
nonfunctional alleles who were on alternative therapy at time of discharge from the 
hospitalization associated with genetic testing and at the first follow-up appointment after 
discharge. Overall, 48.0% and 75.5% of IMs and PMs, respectively, were on alternative 
therapy at first follow-up. At the five institutions using testing strategies with >1 day TAT 
(“Standard Testing”: University of Pittsburgh, University of Florida Health - Shands 
Hospital, University of North Carolina at Chapel Hill, University of Illinois at Chicago, and 
Indiana University), a significantly higher proportion of nonfunctional allele carriers (PMs/
IMs) were receiving alternative therapy at the first follow-appointment versus at time of 
discharge (58% vs 38%, p < 0.0001), whereas the proportion remained consistent (~19%) 
among those without a nonfunctional allele at these same institutions. This is in contrast to 
the institutions that used rapid testing solutions (University of Pennsylvania, University of 
Alabama at Birmingham, and University of Florida – Jacksonville) where similar 
proportions remained on alternative therapy across time-periods. The time from PCI to 
alternative antiplatelet therapy in patients with a nonfunctional allele occurred in less than 1 
day at sites with rapid testing and in a median of one to 10 days at institutions with standard 
single-gene or panel-based testing, respectively. Notably, the proportion of nonfunctional 
allele carriers on alternative therapy at first follow-up in the standard testing group (58%) 
was similar to the proportion of nonfunctional allele carriers on alternative therapy at 
discharge (56%) and at first follow-up (54%) in the rapid testing groups, respectively. The 
proportion of nonfunctional allele carriers on alternative therapy at first follow-up varied 
widely across institutions, ranging from 13% to 100%. Use of alternative therapy in patients 
without a nonfunctional allele was low, ranging from 19% to 30% in both testing groups.
Implementation challenges
Sites reported multiple implementation challenges (Table 4), including obtaining provider 
and stakeholder support, establishing hospital contracts for testing equipment, creating 
laboratory reports, and building CDS systems. Logistical challenges were also commonly 
reported and involved sample processing, return of results to providers and patients, and 
timing of therapy modifications. Some specific challenges varied according to testing 
strategy and implementation model used. For example, the length of time before changes in 
antiplatelet therapy were made after PCI was an issue for institutions that did not use a rapid 
testing platform, while institutions using rapid testing platforms were challenged by the 
requirement to run testing assays within an hour of sample collection with the Spartan RX 
platform, storage of temperature sensitive testing reagents, and the need to recollect 
approximately 10% of samples for repeat genotyping due to initial sample failure. For 
research models, operationalizing the study design and patient recruitment difficulties were 
reported as barriers to implementation. Provider acceptance of clinical recommendations 
based on CYP2C19 genotype and reimbursement for preemptive testing were identified as 
specific challenges in clinical models.
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Lessons learned
Table 5 lists the top lessons learned from clinical implementation of CYP2C19 testing 
reported across sites. In the authors’ experience, clinical pharmacogenomics implementation 
programs require a physician champion and multidisciplinary engagement from key 
stakeholders. If a pre-emptive testing strategy is planned, developing a clear definition of the 
targeted testing population ahead of time is crucial to success. Education efforts need to be 
deployed early and on an ongoing basis to both implementing clinicians and to providers at 
all levels including nurses, nurse practitioners, pharmacists, physicians, and laboratory 
medicine personnel. Establishing close working relationships with informatics groups to 
create test orders, return and store genetic test results appropriately, and build tailored CDS 
alerts was also deemed critical to achieve program success and sustainability. Early adopters 
also emphasized the value of having a designated person or team to act on results and in 
particular, clinical pharmacists, to provide interpretation and increase adherence to 
genotype-informed drug therapy recommendations. Finally, the opportunity to share 
experiences and learn from leaders at other sites who were building similar programs and the 
availability of guidelines/scientific data (e.g., CPIC, PharmGKB) were also valued.
Discussion
CYP2C19 genotype-guided antiplatelet prescribing after PCI is increasing in large academic 
medical centers across the U.S. and beyond. Although early experiences with CYP2C19 
testing have been reported,18,20–25 the current data provide a unique opportunity to compare 
and contrast features of 12 implementation programs. Similarly, the specific challenges 
faced by program leaders and lessons learned in overcoming these obstacles provide a 
valuable perspective for those seeking to implement similar pharmacogenomics programs 
within their institutions.
While several different testing platforms were used among institutions in our study, all sites 
used in-house testing solutions within CAP/CLIA laboratories versus outsourcing to a 
commercial laboratory. The CYP2C19 *2, *3, and *17 alleles were consistently tested, and 
the CPIC guideline phenotype translation tables were used across all institutions. Nearly all 
sites using clinical models submitted bills to third party payers for reimbursement. These 
similarities in the way testing was set up, despite being independent decisions at each site, 
suggests these approaches may be broadly applicable to institutions designing new 
programs. Further, emerging data showing frequent reimbursement across multiple payers26 
and cost-effectiveness of genotype testing at the time of PCI support this strategy.27
A simple metric of implementation program success is whether therapy changes were made 
following pharmacogenomic testing. Data on the frequency of alternative therapy 
prescribing at first follow-up in patients with and without a CYP2C19 nonfunctional allele 
(55-60% versus 20-25%) illustrate, as expected, that genotype results were routinely 
interpreted and used to guide antiplatelet therapy selection. Differences in alternative therapy 
prescribing frequencies within PMs and IMs (75.5% versus 48.0%, respectively) at first 
follow-up further indicate a result predicted PM phenotype was acted upon more frequently. 
Moreover, implementation performance metrics were specific to testing model, and platform 
such that the timing of expected therapy changes was consistent with each institution’s 
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testing TAT. For instance, implementation models that employ rapid testing solutions 
observed similar rates in alternative therapy use in nonfunctional allele carriers at discharge 
and follow-up, indicating that these sites often accomplished therapy changes prior to 
discharge. The Spartan RX system (Spartan Biosciences, Ottawa, ON) offers advantages in 
terms of a rapid TAT; however, centers utilizing this method observed a re-testing rate of up 
to 10%. In contrast, sites that used standard single-gene and platform-based tests often 
reported genotype TAT that exceeded patient length of stay for PCI, and had a lower 
frequency of alternative therapy use in PMs/IMs at discharge. Although frequency of 
alternative therapy use at first follow-up was similar to sites with rapid testing, the logistics 
of achieving drug therapy modifications based on genotype after patient discharge is more 
difficult. Challenges in re-establishing contact with the patient, communication with 
additional providers, and changing drug therapy regimens, especially when patients have 
already received an initial prescription for clopidogrel, can complicate the care process. 
Furthermore, the impact of the delay in therapy changes on clinical outcomes remain 
unclear. However, it should be assumed that delays in changes of antiplatelet therapy in 
nonfunctional allele carriers may be associated with an increase in risk of acute and subacute 
stent thrombosis. Preemptive genotyping has the noted advantage of avoiding the concerns 
of test result TAT, but adds challenges with timely identification of which patient 
populations are likely to be prescribed drugs impacted by targeted variants.28 Similarly, 
reimbursement may be a bigger obstacle within preemptive testing models.29 Overall, while 
it is evident that therapy modifications were accomplished following testing, the 
considerable variability in the proportion of nonfunctional allele carriers on alternative 
therapy at first follow-up across sites (13-100%) underscores the complexity of integrating 
genetic results with patient-specific clinical factors and challenges of implementing 
genotype-guided algorithms in clinical practice.
There was near consensus among sites that return of results to the EHR should include 
discrete data variables such as the gene tested, genotype, and predicted phenotype versus 
scanned “paper” reports or only free text. The availability of consensus nomenclature 
determined by the CPIC term standardization project and common dictionaries will likely 
further encourage the use of standardized, interoperable terminology.9 Together, discrete 
results and standardized terms represent the current gold standard for driving CDS. The use 
of the laboratory reports section of the EHR was ubiquitous, but only a few sites stored 
results in a “problem list” or another location to make the data persistent beyond the current 
patient encounter. Partnering with hospital informatics at the outset of the clinical 
implementation program to establish these requirements, streamline clinical workflows, and 
maintain consistent practices beyond the initial implementation period was deemed crucial. 
While a few sites did post testing results to web portals or provided genotype cards, few 
actively returned results to patients or to downstream providers outside of the institution. 
This remains a future opportunity to further leverage pharmacists and for services 
optimization to improve patient care transitions and adherence to protocols. It will also be 
important to assess patients’ understanding of pharmacogenomics and their overall 
experience with return of test results, as these factors may influence medication adherence 
and can be used to develop educational materials to assist patients who undergo 
pharmacogenomic testing in the future.30
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The summary data and reported lessons learned indicate that a dedicated clinician or team to 
receive the genotype test results is advantageous. This makes sense given the test reports 
from the laboratory rarely included specific therapy recommendations. Personnel with 
expertise in pharmacogenomics such as pharmacists and formal clinical pharmacogenomics 
services are being used to bridge the gap between pharmacogenomic test ordering and 
medication selection.17,31–33 In the current analysis, five sites specifically integrated clinical 
pharmacy experts to receive results, make recommendations, or educate patients and 
providers. As programs grow and are scaled to other sites, dedicated clinical services and/or 
an increased reliance on CDS may be expected.
The need of a physician champion and persistent, ongoing education was reported as both a 
challenge to overcome and a lesson learned. Program leaders thought a champion and active 
dissemination approaches such as in-services to be critical to the launch and ongoing success 
of the implementation, test adoption, and adherence to genotype guided recommendations. 
Ongoing education may be especially important in academic and other centers where 
resident physicians and other trainees rotate through the cardiac catheterization laboratory. 
Genetic literacy is highly variable across providers and is understood to influence 
pharmacogenomic testing adoption.34,35 Educational strategies have been reviewed 
elsewhere36 and their importance should not be undervalued.
As with any new research protocol or clinical program, there is an inherent inefficiency in 
being an early adopter. Whether it was through NIH networks such as IGNITE, eMERGE, 
or the Pharmacogenomics Research Network; professional societies; or even direct 
communication; program leaders emphasized the value they found in collaboration and 
learning from others working to overcome common challenges. To help catalyze efforts, by 
institutions involved in this work are available in the IGNITE Network SPARK Toolbox at 
www.ignite-genomics.org.
Ultimately, decisions to develop a CYP2C19 genotype-guided prescribing program and its 
design are driven by clinical evidence of value of these services. Recent guidelines state a 
preference for alternative therapy over clopidogrel in patients with ACS treated with PCI 
based on clinical trial data showing improved outcomes with prasugrel and ticagrelor over 
clopidogrel in this setting, albeit at an increased bleeding risk.2 However, approximately 
30% of clopidogrel-treated patients in these ACS trials would have had a nonfunctional 
CYP2C19 allele and reduced response to clopidogrel, as has been demonstrated in post-hoc 
genetic sub-studies.12,14,37–39 Even with increased use of alternative therapies early after 
PCI, there remains an argument that genotyping has an important role in informing chronic 
antiplatelet therapy. In particular, clopidogrel may be more appropriate for a patient with a 
normal metabolizer phenotype and when the patient could not afford or tolerate one of the 
newer agents. Prasugrel and ticagrelor are also commonly prescribed in patients with stable 
coronary artery disease undergoing PCI, even though these agents are only indicated for 
ACS and there are no randomized clinical trial data showing evidence of superiority of 
alternative therapy in non-ACS indications. Clinical guidelines do not endorse use of 
alternative therapy after PCI for stable coronary artery disease, yet a finding of a 
nonfunctional allele in patients with stable coronary disease prescribed clopidogrel may 
provide support the use alternative therapy in these cases.2 Recent real-world data suggest 
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clopidogrel still remains the most commonly prescribed antiplatelet agent after PCI and that 
there may be a role for genotyping in this scenario.5,16 Among patients with genotype 
results available early after PCI, initiation of alternative antiplatelet therapy over clopidogrel 
in those with a nonfunctional CYP2C19 allele resulted in a significant reduction in major 
adverse cardiovascular events.16 These data and similarly positive results from other clinical 
implementation studies and small randomized controlled trials may prompt others to move 
toward a genotype-guided approach to prescribing antiplatelet therapy in the PCI setting.
20–23,26,40
Several limitations to the analysis should be noted. Selection bias is possible as all 
institutions were recruited from a common research network and approaches to 
implementation may therefore be similar for this reason. Similarly, while most institutions 
were university hospitals, the experience at Sanford Health indicates that implementation is 
feasible and well-accepted within a large group of private multispecialty practices. As 
genotype-based prescribing is further expanded to more diverse or non-academic settings, 
preemptive testing or rapid genotyping platforms may be considered so that results are 
available at the time of or soon after PCI. In the current analysis, data availability was also 
not consistent as not all sites tracked medication prescribing downstream of the genetic 
testing, and the number of eligible patients who were not genotyped was not recorded as a 
metric of algorithm use. Future work will focus on collecting these data, as well as the 
sustainability of genotype testing and genotype-guided medication selection over time, to 
understand which program features are necessary to drive optimal prescribing. Finally, 
findings may be specific to pharmacogenomics implementation in the PCI population and 
may not be broadly applicable to other populations.
Overall, clinical implementation of CYP2C19 genotype-guided antiplatelet prescribing after 
PCI is becoming increasingly common. Data and experiences from 12 early-adopter 
institutions presented herein provide real-world insight for institutions seeking to implement 
genotype-guided antiplatelet therapy, and strategies to overcome barriers likely to be 
encountered. Similarly, lessons learned may be applicable to clinical pharmacogenomics 
implementation efforts for additional gene-drug pairs and to genomic medicine more 
broadly.
Methods
Our goal was to summarize and compare implementation experiences of early adopters of 
CYP2C19 pharmacogenomic testing to guide antiplatelet medication selection. The study 
population included 12 large academic institutions within the IGNITE Network 
Pharmacogenetics Working Group (five funded institutions and seven affiliate members)1 
who have tested 6340 patients for CYP2C19 alleles (see Table S1 for a breakdown by site).
Data collection was completed at each site through a structured electronic spreadsheet 
disseminated to each site leader. Specific data elements were selected and definitions were 
refined through open discussions at several in-person meetings and conference calls from 
September 2016 to May 2017. The tool was then pilot-tested for feasibility prior to 
dissemination to all sites. Areas of focus included the baseline genetics testing landscape at 
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each site, stakeholder involvement, the design of each implementation program, testing 
approaches, informatics setup, return of results procedures, and any education provided. 
Eight of the 12 sites also provided data on antiplatelet medication use after genotyping 
(1858 total patients). Data cleaning was accomplished iteratively through direct follow-up 
communications. All data elements collected were reported.
Program performance metrics including testing turnaround times, reported predicted 
phenotype frequencies, and drug prescribing patterns were also sought from local EHRs or 
research study data sources when available. All data abstraction and reporting was approved 
by local institutional review board at each site. Descriptive statistics were reported by 
institution and proportions of patients with specific test results prescribed alternative therapy 
were compared using chi square testing. Finally, common challenges that must be overcome 
and recommendations (lessons learned) for those considering similar implementations in the 
future were solicited from site investigators and aggregated to a consensus lists through 
multiple rounds of telephone conference call discussions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Study Highlights
What is the current knowledge on the topic?
While recent data supports CYP2C19 genotype-guided prescribing of antiplatelet therapy 
following percutaneous coronary intervention and genetic testing is increasingly 
deployed in clinical practice, pharmacogenomic testing programs are challenging to 
implement.
What questions did this study address?
What are the common challenges, pathways to operationalization, initial performance 
metrics, and lessons learned among 12 sites that are early adopters of pharmacogenomics 
testing?
What does this study add to our knowledge?
Common and differentiating features (e.g. testing approaches, how results are 
communicated, clinical decision support, provider and patient education, and methods to 
support the translation of emerging evidence to clinical practice) are presented along with 
a discussion of implementations challenges faced and lessons learned.
How might this change clinical pharmacology or translational science?
Disseminating the implementation experiences of early-adopters of pharmacogenomics 
testing provides valuable perspectives for those seeking to implement similar 
pharmacogenomics programs within their institutions.
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Figure 1. Modalities of communication and education
Approaches for providers and patients that were reported by sites are listed in order of 
decreasing scalability.
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Figure 2. Proportion of patients carrying nonfunctional alleles on alternative (ALT) therapy at 
discharge and first follow-up
Sites using standard (single gene- and panel- based testing with >1 day TAT) and rapid (right 
panel) testing are grouped in the left and right panels, respectively. Tables below indicate 
number of patients in each group. * p < 0.0001 by Chi-square.
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Table 2
Pharmacogenomic testing
Institution Gene(s) tested Platform CYP2C19 Alleles reported
University of Alabama at Birmingham CYP2C19 only Spartan RX, Spartan Biosciences 
(Ottawa, ON)
*2, *3, *17
University of Pennsylvania CYP2C19 only Spartan RX, Spartan Biosciences 
(Ottawa, ON)
*2, *3, *17
University of Florida Health, Jacksonville CYP2C19 only Spartan RX, Spartan Biosciences 
(Ottawa, ON)
*2, *3, *17
University of Illinois at Chicago CYP2C19 only eSensor XT-8, GenMark Diagnostics 
(Carlsbad, CA)
*2, *3, *4,*5, *6, *8,, *9, *10, *13,*17
University of Florida Health, Shands 
Hospital, Gainesville
CYP2C19 only* eSensor XT-8, GenMark Diagnostics 
(Carlsbad, CA)
*2, *3, *4,*5, *6, *8,*9, *10, *13,*17
University of Pittsburgh, UPMC 
Presbyterian Hospital
CYP2C19 only eSensor XT-8, GenMark Diagnostics 
(Carlsbad, CA)
*2, *3, *4,*5, *6, *7,*8, *9, *10,*17
University of North Carolina at Chapel Hill CYP2C19 only Custom Taqman® assay, 
ThermoFisher (Waltham, MA)
*2, *3, *17
University of Maryland, Baltimore CYP2C19 only Custom Taqman® assay, 
ThermoFisher (Waltham, MA)
*2, *3, *4,*6, *8, *17
Sanford Health CYP2C19 only BeadXpress ADME Panel, Illumina 
(San Diego, CA)
*2, *3, *4,*5, *6, *8,*12, *17
Indiana University Panel Custom Taqman® assay, 
ThermoFisher (Waltham, MA)
*2, *3, *4,*4B, *6, *8,*10, *17
Icahn School of Medicine at Mount Sinai 
and the Mount Sinai Hospital
Panel MassARRAY, Agena Biosciences 
(San Diego, CA)
*2, *3, *4,*5, *6, *7,*8, *17
Vanderbilt University Panel Custom QuantStudio® assay, 
ThermoFisher (Waltham, MA)
*2, *3, *4,*5, *6, *7,*8, *17
*
Initially launched with multi-gene panel based testing, but changed to CYP2C19 testing only after the first year
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Table 4
Primary Implementation Challenges
• Provider/stakeholder buy-in
• Establishing laboratory contracts with hospital
• EHR formatting of laboratory reports
• Development of clinical decision support
• Logistics of:
 ○ sample collection in cardiac catheterization laboratory or as an outpatient
 ○ location of rapid testing devices and freezers
 ○ getting results to appropriate providers
 ○ returning of results prior to patient discharge due to testing TAT
 ○ implementation of therapy changes after patient discharge
 ○ delays in therapy changes until after clinical decision alert fires in the EHR system
 ○ notifying patients they were tested and of their results
• Acceptance of recommendations based on testing results
• Number of samples that needed to be recollected (for rapid testing platforms)
• Study design (for research implementations)
• Patient recruitment (for research implementations)
• Billing/reimbursement for pre-emptive testing
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Table 5
Lessons Learned
• Design pharmacogenomics implementation program for the health system patient population
• Identify a physician champion and engage key stakeholders
• Target the right patient population for preemptive testing
• Preemptive testing reduced issues around TAT, but introduced challenges with patient identification and reimbursement
• Engage and educate clinicians early and repeatedly throughout the implementation process
• Partner with hospital informatics to create clinical decision support tools and solve ongoing EHR challenges
• A designated person or team to respond to results improves efficiency of therapy changes
• Integrate clinical pharmacists to ensure adherence to the implementation algorithm and appropriate follow-up
• Provide ongoing education programs for all health care providers
• Learn from published experiences of early implementers, domain expert groups (CPIC)
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